All the Drug Class Drugs
Antineoplastic, Engineered Autologous T Cell Immunotherapy product. idecabtagene vicleucel 260 - 500 x 10^6. For autologous use only. Tmt. consists of a sgle dose for inf. containing a dispersion of CAR-pos. viable T cells in one or more bags. The target dose is 420 x 106 CAR-pos. viable T cells within a range of 260 to 500 x 106 CAR-pos. viable T cells.
For adults with relapsed and refractory multiple myeloma who have received at least two prior ther., incl. an immunomodulatory agent, a proteasome inhib. and an anti-CD38 antibody and have demonstr. dis. progress. on the last ther.
C/I: Hypersens.
Antineoplastic. Fluorouracil 50 mg / 1 g. CREAM: 20 g. Pre-malignant cond:
Apply thinly to affect. area 1-2 x dly.
Malignant cond: Apply 1-2 x dly under
occlusive dressing where practical.
Should not harm healthy skin. Cont.
tmt. until marked inflamm. resp. from
treated area. Alleviate severe
discomfort with steroid cream. Usual
tmt. 3-4 wks or longer. Healing may
take up to 1-2 months after stopping
ther. Use in child not recommend.
C/I: Hypersens., pregn., lact. co-admin
antiviral nucleoside drugs.
Anti-Androgen, Antineoplastic. Apalutamide 60 mg. F.C. TABS.: 120. 240 mg (four 60 mg tabs.) admin. orally once dly. Swallow the tabs. whole. The drug can be taken with / without food. Pts. should also receive a gonadotropin-releasing hormone (GnRH) analog concur. or should have had a bilater. orchiectomy.
Dose Modific.: If a pt. experiences a greater than or equal to Grade 3 toxic. or an intoler. side effect, hold dosing until sympt. improve to less than or equal to Grade 1 or original grade, then resume at the same dose or a reduced dose (180 mg or 120 mg), if warranted.
Tmt. of pts. with non-metast., castrat.-resist. prostate cancer (NM-CRPC).
C/I: Hypersens.
Antineoplastic. Fluorouracil 50 mg/ 1 gr. Antimetabolite (purine analog) fluorouracil 5% w/w
Alum. tube, Cr. dermal use , 20 g.
To be applied 1 or 2 / d in pre-malign., w/o occlusive dressing. In malign., 1 or 2 / d under an occlusive dressing where practicable. Tmt. to be contin. until there is marked inflammatory resp. from treated area, prefer. with some erosion in the case of pre-malignant condit. The usual duration of treatment for an initial course of ther. is 3-4 weeks.
| Healing may not be complete until 1-2 mo. after ther. is stopped. See prescript. details. |
Antineoplast. to treat actinic keratosis multipl. and superf. basal cell carcinoma in adlts.
C/I: Hypersens., pregn., breastfeed., conc. use with antiviral nucleosides.
Antineoplastic, Immunomodulator Agent. Talimogene Laherparepvec 10^6 PFU/ml, 10^8 PFU/ml. Talimogene laherparepvec, attenuate. herpes S. virus type-1 (HSV-1) derived by funct. deletion of 2 genes (ICP34.5& ICP47) and insert. of coding sequen. for human granulocyte macrophage colony-stimulat. factor (GM-CSF).
106- 1×106 (1 million) plaque form. units (PFU)/mL.
108- 1×108 (100 million) plaque form. units (PFU)/mL
VIAL (sol. for inj.): 1. Dosage must be ajust. individ.
Tmt. of adult. with unresect. melanoma that is regional. or distant. metastat. (Stage IIIB, IIIC and IVM1a) with no bone, brain, lung or other visceral dis.
C/I: Pts. with a history of hypersens. to talimogene laherparepvec.
Severely immunocompromised pts. (e.g. pts. with severe congen. or acquired cellular and/or humoral immune deficien.).
Antineoplastic. Sotorasib 120 mg, 240 mg. Film-coated tablets: 960 mg (eight 120 mg tabs or four 240 mg tablets) once daily, at the same time each day.
Tmt. of adlt. Pts. with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an approved test, who have received at least one prior systemic therapy.
C/I: Hypersens.
